[{"id":11,"action_date":"2026-08-27","actor":"court","actor_detail":"U.S. Court of Appeals for the Fifth Circuit","jurisdiction":"US","instrument":"opinion","target":null,"drugs":"tirzepatide","statute":"Administrative Procedure Act","summary":"Per curiam opinion, not designated for publication, in Outsourcing Facilities Association et al. v. FDA et al., affirming the district court and rejecting the challenge to FDA's determination that the tirzepatide shortage was resolved.","source_url":"https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf","docket":"No. 25-10600","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":1},{"id":10,"action_date":"2026-08-27","actor":"court","actor_detail":"U.S. Court of Appeals for the Fifth Circuit","jurisdiction":"US","instrument":"opinion","target":null,"drugs":"semaglutide","statute":"Administrative Procedure Act","summary":"Per curiam opinion, not designated for publication, in Outsourcing Facilities Association et al. v. FDA et al., affirming the district court and rejecting the challenge to FDA's determination that the semaglutide shortage was resolved.","source_url":"https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf","docket":"No. 25-10758","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":2},{"id":8,"action_date":"2026-06-26","actor":"federal_register","actor_detail":"Federal Register (FDA notice)","jurisdiction":"US","instrument":"proposed_rule","target":null,"drugs":"semaglutide,tirzepatide,liraglutide","statute":"FDCA 503B(a)(2)","summary":"Notice, 91 FR 38719, extending the comment period on the May 1, 2026 proposal by 30 days, to July 30, 2026.","source_url":"https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal","docket":"FDA-2018-N-3240","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":7},{"id":9,"action_date":"2026-06-15","actor":"fda","actor_detail":"FDA","jurisdiction":"US","instrument":"guidance","target":null,"drugs":null,"statute":null,"summary":"Web page titled \"FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs\" (content current as of June 15, 2026), stating what FDA regards as false or misleading promotion of compounded drugs and directing readers to the warning-letter database.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs","docket":null,"status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":42,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Maximus Health, Inc. dba Maximus","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maximus-health-inc-dba-maximus-730095-06082026","docket":"MARCS-CMS 730095","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":41,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Clover Meds LLC dba Clover Meds","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/clover-meds-llc-dba-clover-meds-728234-06082026","docket":"MARCS-CMS 728234","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":40,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Nova Vascular LLC dba NOVARX","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nova-vascular-llc-dba-novarx-728290-06082026","docket":"MARCS-CMS 728290","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":39,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Joi and Blokes dba Joi + Blokes","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/joi-and-blokes-dba-joi-blokes-728283-06082026","docket":"MARCS-CMS 728283","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":38,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Roen Health, Inc. dba RoenRx","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/roen-health-inc-dba-roenrx-728293-06082026","docket":"MARCS-CMS 728293","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":37,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"OrderlyMeds LLC dba OrderlyMeds","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/orderlymeds-llc-dba-orderlymeds-728291-06082026","docket":"MARCS-CMS 728291","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":36,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"FITISH","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitish-728280-06082026","docket":"MARCS-CMS 728280","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":35,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Ready Med","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ready-med-730317-06082026","docket":"MARCS-CMS 730317","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":34,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Ezra Holdco LLC dba Ezra","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ezra-holdco-llc-dba-ezra-730995-06082026","docket":"MARCS-CMS 730995","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":33,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Medica Weight Loss","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medica-weight-loss-728284-06082026","docket":"MARCS-CMS 728284","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":32,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Momentum Health 360 dba Momentum Health","drugs":"semaglutide,tirzepatide,liraglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide, liraglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/momentum-health-360-dba-momentum-health-728286-06082026","docket":"MARCS-CMS 728286","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":31,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"D&H Medical Services","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dh-medical-services-728238-06082026","docket":"MARCS-CMS 728238","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":30,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Public Health Solution LLC dba DrMedHealth","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/public-health-solution-llc-dba-drmedhealth-728278-06082026","docket":"MARCS-CMS 728278","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":29,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Nexlife Inc. dba Nexlife","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nexlife-inc-dba-nexlife-730096-06082026","docket":"MARCS-CMS 730096","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":28,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Glow Medispa, LLC dba Mint Med","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glow-medispa-llc-dba-mint-med-730390-06082026","docket":"MARCS-CMS 730390","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":27,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"VivioMD Group LLC dba VivioMD","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viviomd-group-llc-dba-viviomd-728295-06082026","docket":"MARCS-CMS 728295","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":26,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Thrivelab Co. dba Thrivelab","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thrivelab-co-dba-thrivelab-728294-06082026","docket":"MARCS-CMS 728294","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":25,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Amie Health, Inc. dba Amie","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amie-health-inc-dba-amie-728276-06082026","docket":"MARCS-CMS 728276","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":24,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Trinity HealthCare Supply, LLC dba altRx","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trinity-healthcare-supply-llc-dba-altrx-728236-06082026","docket":"MARCS-CMS 728236","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":23,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Eden Health International Inc. dba Eden","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eden-health-international-inc-dba-eden-728279-06082026","docket":"MARCS-CMS 728279","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":22,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Altru Telehealth, LLC dba Altru Telehealth","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/altru-telehealth-llc-dba-altru-telehealth-728274-06082026","docket":"MARCS-CMS 728274","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":21,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"FitRX, LLC dba AM RX","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-am-rx-728275-06082026","docket":"MARCS-CMS 728275","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":20,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Nexus Health Solutions LLC dba Harper Meds","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nexus-health-solutions-llc-dba-harper-meds-728281-06082026","docket":"MARCS-CMS 728281","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":19,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"HydraMed IV LLC dba HydraMed","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hydramed-iv-llc-dba-hydramed-728282-06082026","docket":"MARCS-CMS 728282","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":18,"action_date":"2026-06-08","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"NativeMed LLC dba NativeMed","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nativemed-llc-dba-nativemed-728287-06082026","docket":"MARCS-CMS 728287","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":7,"action_date":"2026-05-01","actor":"federal_register","actor_detail":"Federal Register (FDA notice)","jurisdiction":"US","instrument":"proposed_rule","target":null,"drugs":"semaglutide,tirzepatide,liraglutide","statute":"FDCA 503B(a)(2)","summary":"Notice, 91 FR 23431, proposing not to include semaglutide, tirzepatide, or liraglutide on the 503B bulks list. Comments were due June 30, 2026, later extended to July 30, 2026. No final determination had been published when this entry was verified.","source_url":"https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal","docket":"FDA-2018-N-3240","status":"open","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":6,"action_date":"2026-04-30","actor":"fda","actor_detail":"FDA","jurisdiction":"US","instrument":"press_announcement","target":null,"drugs":"semaglutide,tirzepatide,liraglutide","statute":"FDCA 503B","summary":"Press announcement titled \"FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List\", stating FDA found no clinical need for outsourcing facilities to compound these drugs from bulk substances.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list","docket":null,"status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":5,"action_date":"2026-03-03","actor":"fda","actor_detail":"FDA","jurisdiction":"US","instrument":"press_announcement","target":null,"drugs":"semaglutide,tirzepatide","statute":null,"summary":"Press announcement titled \"FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s\", describing claims implying sameness with FDA-approved products and obscuring product sourcing. The 30 letters are dated February 20, 2026 and are listed here individually.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s","docket":null,"status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":72,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Genesis Health International Inc. dba Genesis","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genesis-health-international-inc-dba-genesis-721451-02202026","docket":"MARCS-CMS 721451","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":71,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"FitRX, LLC dba FitRx","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-fitrx-717987-02202026","docket":"MARCS-CMS 717987","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":70,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Aspen Aesthetics dba Fifty 410","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aspen-aesthetics-dba-fifty-410-721481-02202026","docket":"MARCS-CMS 721481","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":69,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/deluxe-iv-aesthetics-pllc-dba-deluxe-iv-and-aesthetics-721447-02202026","docket":"MARCS-CMS 721447","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":68,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"BluefitMD","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bluefitmd-721446-02202026","docket":"MARCS-CMS 721446","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":67,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Bliv Wellness LLC dba Bliv","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bliv-wellness-llc-dba-bliv-721479-02202026","docket":"MARCS-CMS 721479","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":66,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Belle Health LLC dba Belle","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/belle-health-llc-dba-belle-721795-02202026","docket":"MARCS-CMS 721795","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":65,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Dripgym Mobile Parent, LLC dba Amp Health","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dripgym-mobile-parent-llc-dba-amp-health-717992-02202026","docket":"MARCS-CMS 717992","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":64,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Alan Health Technologies Inc. dba Alan","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/alan-health-technologies-inc-dba-alan-721814-02202026","docket":"MARCS-CMS 721814","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":63,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"24HrDoc, Inc. dba 24HrDoc","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/24hrdoc-inc-dba-24hrdoc-717984-02202026","docket":"MARCS-CMS 717984","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":62,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"NewSelf Limited dba NewSelf","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/newself-limited-dba-newself-721472-02202026","docket":"MARCS-CMS 721472","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":61,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Newman Clinic, PLLC dba Newman Clinic","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/newman-clinic-pllc-dba-newman-clinic-721470-02202026","docket":"MARCS-CMS 721470","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":60,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"MEDVi, LLC dba MEDVi","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medvi-llc-dba-medvi-721455-02202026","docket":"MARCS-CMS 721455","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":59,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Better Health Labs, Inc. dba Measured","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/better-health-labs-inc-dba-measured-721454-02202026","docket":"MARCS-CMS 721454","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":58,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"MaxLife Technologies Inc. dba Maxlife","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maxlife-technologies-inc-dba-maxlife-721453-02202026","docket":"MARCS-CMS 721453","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":57,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Levity Inc. dba Levity","drugs":"semaglutide,liraglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, liraglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026","docket":"MARCS-CMS 717990","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":56,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Kin Meds","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kin-meds-721450-02202026","docket":"MARCS-CMS 721450","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":55,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Join Josie","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/join-josie-717986-02202026","docket":"MARCS-CMS 717986","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":54,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Ivim Services LLC dba Ivim","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ivim-services-llc-dba-ivim-721816-02202026","docket":"MARCS-CMS 721816","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":53,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Good Girl LLC dba GoodGirlRX","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/good-girl-llc-dba-goodgirlrx-721449-02202026","docket":"MARCS-CMS 721449","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":52,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"PharmaZee","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmazee-721473-02202026","docket":"MARCS-CMS 721473","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":51,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Peaks Curative, LLC dba Peaks","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peaks-curative-llc-dba-peaks-721817-02202026","docket":"MARCS-CMS 721817","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":50,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Viv Health, Inc. dba VIV RX","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viv-health-inc-dba-viv-rx-721818-02202026","docket":"MARCS-CMS 721818","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":49,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Weightless Medical LLC dba WeightCare","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/weightless-medical-llc-dba-weightcare-721478-02202026","docket":"MARCS-CMS 721478","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":48,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Refills Health, LLC dba Refills Health","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/refills-health-llc-dba-refills-health-721475-02202026","docket":"MARCS-CMS 721475","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":47,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Strut Health, LLC dba Strut","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/strut-health-llc-dba-strut-721448-02202026","docket":"MARCS-CMS 721448","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":46,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Kare Solutions, LLC dba Zappy","drugs":"semaglutide,tirzepatide,liraglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide, liraglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kare-solutions-llc-dba-zappy-717991-02202026","docket":"MARCS-CMS 717991","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":45,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Lean Rx, Inc. dba SkinnyRx","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-rx-inc-dba-skinnyrx-717989-02202026","docket":"MARCS-CMS 717989","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":44,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Zeuss LLC dba Zeuss","drugs":"tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zeuss-llc-dba-zeuss-717985-02202026","docket":"MARCS-CMS 717985","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":43,"action_date":"2026-02-20","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Premium Health Management Inc. dba Premium Health","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c), 503(b)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"False & Misleading Claims/Misbranded (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/premium-health-management-inc-dba-premium-health-721474-02202026","docket":"MARCS-CMS 721474","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":4,"action_date":"2026-02-06","actor":"fda","actor_detail":"FDA","jurisdiction":"US","instrument":"press_announcement","target":null,"drugs":"semaglutide,tirzepatide","statute":"FDCA 503A","summary":"Press announcement titled \"FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs\", stating an intent to restrict GLP-1 active pharmaceutical ingredients for non-approved compounded drugs, referring to warning letters sent in fall 2025 over misleading direct-to-consumer advertising, and naming Hims & Hers.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs","docket":null,"status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":17,"action_date":"2026-01-01","actor":"state_board","actor_detail":"Indiana Board of Pharmacy","jurisdiction":"IN","instrument":"order","target":null,"drugs":"retatrutide","statute":null,"summary":"Reported: denial of a nonresident pharmacy license tied to research-labeled peptides and retatrutide. Party and date not identified.","source_url":null,"docket":null,"status":"no_information","status_reason":"secondhand item; no board order located","verified_on":null,"related_id":null},{"id":16,"action_date":"2026-01-01","actor":"state_board","actor_detail":"Alabama (agency not identified)","jurisdiction":"AL","instrument":"order","target":null,"drugs":"retatrutide","statute":null,"summary":"Reported: an asset freeze and clinic closure tied to research-labeled peptides and retatrutide. Agency, party, and date not identified.","source_url":null,"docket":null,"status":"no_information","status_reason":"secondhand item; no order located","verified_on":null,"related_id":null},{"id":15,"action_date":"2026-01-01","actor":"state_board","actor_detail":"Connecticut (agency not identified)","jurisdiction":"CT","instrument":"settlement","target":null,"drugs":"retatrutide","statute":null,"summary":"Reported: a $300,000 settlement tied to research-labeled peptides and retatrutide. Agency, party, and date not identified.","source_url":null,"docket":null,"status":"no_information","status_reason":"secondhand item; no settlement document located","verified_on":null,"related_id":null},{"id":13,"action_date":"2026-01-01","actor":"state_board","actor_detail":"California State Board of Pharmacy; Medical Board of California","jurisdiction":"CA","instrument":"rule","target":null,"drugs":"semaglutide","statute":null,"summary":"Reported: updated compounded drug preparation rules effective January 2026 and inspection scrutiny of compounded GLP-1 prescriptions; Medical Board discipline of prescribers for post-shortage compounded semaglutide without documented patient-specific justification. Reported date is approximate.","source_url":null,"docket":null,"status":"no_information","status_reason":"owner working notes; the rule text and disciplinary orders have not been located and linked","verified_on":null,"related_id":null},{"id":127,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Healthon Inc. dba Healthon","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthon-inc-dba-healthon-719809-09092025","docket":"MARCS-CMS 719809","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":126,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Curex","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curex-716821-09092025","docket":"MARCS-CMS 716821","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":125,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Elite Health Center","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/elite-health-center-715869-09092025","docket":"MARCS-CMS 715869","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":124,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Matthew Stern, CEO MyStart Health LLC.","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/matthew-stern-ceo-mystart-health-llc-714755-09092025","docket":"MARCS-CMS 714755","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":123,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Fancy Meds, LLC dba Fancy Meds","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fancy-meds-llc-dba-fancy-meds-716487-09092025","docket":"MARCS-CMS 716487","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":122,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"EA WORKS Limited Liability Company dba Trust Labs","drugs":"semaglutide,tirzepatide,retatrutide","statute":"FDCA 301(a), 501(a), 502(f), 503B(b), 503A(b), 503B(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide, retatrutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ea-works-limited-liability-company-dba-trust-labs-715798-09092025","docket":"MARCS-CMS 715798","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":121,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Remedy Meds","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/remedy-meds-716830-09092025","docket":"MARCS-CMS 716830","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":120,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Dr. Gater’s Weight Loss & Wellness","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dr-gaters-weight-loss-wellness-712866-09092025","docket":"MARCS-CMS 712866","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":119,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Invigorate Med Spa","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/invigorate-med-spa-715872-09092025","docket":"MARCS-CMS 715872","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":118,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Intimate Rose","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intimate-rose-716458-09092025","docket":"MARCS-CMS 716458","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":117,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Healthy Male","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthy-male-716506-09092025","docket":"MARCS-CMS 716506","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":116,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"All American Wellness","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/all-american-wellness-715991-09092025","docket":"MARCS-CMS 715991","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":115,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Canada Med Stop","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/canada-med-stop-716517-09092025","docket":"MARCS-CMS 716517","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":114,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Body Good Studio","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/body-good-studio-716460-09092025","docket":"MARCS-CMS 716460","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":113,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"ASN-LABS","drugs":"semaglutide,tirzepatide,retatrutide","statute":"FDCA 301(a), 501(a), 502(f), 503B(b), 503A(b), 503B(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide, retatrutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/asn-labs-716459-09092025","docket":"MARCS-CMS 716459","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":112,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"GLP-1 Solution","drugs":"semaglutide,tirzepatide,retatrutide","statute":"FDCA 301(a), 501(a), 502(f), 503B(b), 503A(b), 503B(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide, retatrutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025","docket":"MARCS-CMS 715883","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":111,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Lumimeds","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lumimeds-716510-09092025","docket":"MARCS-CMS 716510","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":110,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Mane & Steel, LLC. dba Mane & Steel","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mane-steel-llc-dba-mane-steel-716455-09092025","docket":"MARCS-CMS 716455","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":109,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"MedClub by Dr. Jenn","drugs":"semaglutide,retatrutide","statute":"FDCA 301(a), 501(a), 502(f), 503B(b), 503A(b), 503B(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, retatrutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medclub-dr-jenn-712126-09092025","docket":"MARCS-CMS 712126","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":108,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Hims & Hers Health, Inc. dba Hims","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hims-716567-09092025","docket":"MARCS-CMS 716567","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":107,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"directmeds.com, Inc. dba DirectMeds","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/directmedscom-inc-dba-directmeds-716822-09092025","docket":"MARCS-CMS 716822","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":106,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"SemaBio","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/semabio-715866-09092025","docket":"MARCS-CMS 715866","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":105,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Nuvo Life Health Inc. dba Nuvo Life Health","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuvo-life-health-inc-dba-nuvo-life-health-715794-09092025","docket":"MARCS-CMS 715794","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":104,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"eDrugstore","drugs":"tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/edrugstore-716505-09092025","docket":"MARCS-CMS 716505","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":103,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"EvoLife Wellness","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evolife-wellness-715507-09092025","docket":"MARCS-CMS 715507","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":102,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Cosmo Medical Spa dba Cosmo Med Spa","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmo-medical-spa-dba-cosmo-med-spa-715873-09092025","docket":"MARCS-CMS 715873","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":101,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Elevate Your Wellness LLC, dba Elevated","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/elevate-your-wellness-llc-dba-elevated-719811-09092025","docket":"MARCS-CMS 719811","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":100,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"SimpleRx","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/simplerx-715874-09092025","docket":"MARCS-CMS 715874","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":99,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Bioverse, Inc. dba Bioverse","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bioverse-inc-dba-bioverse-716508-09092025","docket":"MARCS-CMS 716508","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":98,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"inspire.clinic","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/inspireclinic-715799-09092025","docket":"MARCS-CMS 715799","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":97,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Reset IV, LLC dba Reset IV","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/reset-iv-llc-dba-reset-iv-716488-09092025","docket":"MARCS-CMS 716488","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":96,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"HealBerry","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healberry-719809-09092025","docket":"MARCS-CMS 719809","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":95,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"TRYM Health, Inc. dba TRYM Health","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trym-health-inc-dba-trym-health-716699-09092025","docket":"MARCS-CMS 716699","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":94,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Master Pharmaceuticals Group","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/master-pharmaceuticals-group-715800-09092025","docket":"MARCS-CMS 715800","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":93,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Sprout Health Partners LLC dba Sprout Health","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sprout-health-partners-llc-dba-sprout-health-715879-09092025","docket":"MARCS-CMS 715879","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":92,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Slendid","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/slendid-716700-09092025","docket":"MARCS-CMS 716700","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":91,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"JulyMD","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/julymd-716828-09092025","docket":"MARCS-CMS 716828","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":90,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Lyfe Rx","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lyfe-rx-09092025","docket":null,"status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":89,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Las Villas Health Care LLC dba Villas Health","drugs":"semaglutide,sildenafil","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, sildenafil.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/las-villas-health-care-llc-dba-villas-health-716504-09092025","docket":"MARCS-CMS 716504","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":88,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Tuyo Health, Inc. dba Tuyo Health","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tuyo-health-inc-dba-tuyo-health-716502-09092025","docket":"MARCS-CMS 716502","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":87,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Vitals RX","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vitals-rx-715868-09092025","docket":"MARCS-CMS 715868","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":86,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"The HCG Institute","drugs":"semaglutide,hcg","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, hcg.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hcg-institute-716512-09092025","docket":"MARCS-CMS 716512","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":85,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Lovely Meds, Inc. dba Lovely Meds","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lovely-meds-inc-dba-lovely-meds-716829-09092025","docket":"MARCS-CMS 716829","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":84,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Try Nova","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/try-nova-716695-09092025","docket":"MARCS-CMS 716695","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":83,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"iVisitDoc, Inc. dba iVisitDoc","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ivisitdoc-inc-dba-ivisitdoc-716826-09092025","docket":"MARCS-CMS 716826","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":82,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"ybycmeds","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ybycmeds-715878-09092025","docket":"MARCS-CMS 715878","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":81,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Lean Dreams LLC dba LeanDreams","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-dreams-llc-dba-leandreams-716697-09092025","docket":"MARCS-CMS 716697","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":80,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"FitRX, LLC dba Zealthy","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-zealthy-716501-09092025","docket":"MARCS-CMS 716501","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":79,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"GenLabMeds","drugs":"semaglutide,tirzepatide,retatrutide","statute":"FDCA 301(a), 501(a), 502(f), 503B(b), 503A(b), 503B(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide, retatrutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genlabmeds-713650-09092025","docket":"MARCS-CMS 713650","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":78,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Amazing Meds","drugs":"semaglutide,retatrutide","statute":"FDCA 301(a), 501(a), 502(f), 503B(b), 503A(b), 503B(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, retatrutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amazing-meds-715506-09092025","docket":"MARCS-CMS 715506","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":77,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Hims & Hers Health, Inc. dba Hers","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hers-716825-09092025","docket":"MARCS-CMS 716825","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":76,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Healthy Living Clinic","drugs":"semaglutide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthy-living-clinic-09092025","docket":null,"status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":75,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Expert Aesthetics","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/expert-aesthetics-715796-09092025","docket":"MARCS-CMS 715796","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":74,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"FWD Care, Inc. dba FWD","drugs":"semaglutide,tirzepatide","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fwd-care-inc-dba-fwd-716696-09092025","docket":"MARCS-CMS 716696","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":73,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA CDER","jurisdiction":"US","instrument":"warning_letter","target":"Get.Fit.Medical, LLC dba Get.Fit.Medical","drugs":"semaglutide,tirzepatide,sildenafil,tadalafil","statute":"FDCA 301(a), 502(a), 502(bb), 301(c)","summary":"Warning letter from FDA's Center for Drug Evaluation and Research. Subject as titled by FDA: \"Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)\". Drugs named in the letter: semaglutide, tirzepatide, sildenafil, tadalafil.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/getfitmedical-llc-dba-getfitmedical-715801-09092025","docket":"MARCS-CMS 715801","status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":3,"action_date":"2025-09-09","actor":"fda","actor_detail":"FDA","jurisdiction":"US","instrument":"press_announcement","target":null,"drugs":null,"statute":null,"summary":"Press announcement titled \"FDA Launches Crackdown on Deceptive Drug Advertising\", announcing thousands of untitled letters and roughly 100 cease-and-desist letters over direct-to-consumer advertising. The announcement does not mention telehealth companies or compounded GLP-1 drugs; the 55 telehealth warning letters listed here carry the same date.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-launches-crackdown-deceptive-drug-advertising","docket":null,"status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":12,"action_date":"2025-07-01","actor":"state_board","actor_detail":"Ohio Board of Pharmacy","jurisdiction":"OH","instrument":"guidance","target":null,"drugs":"semaglutide,tirzepatide","statute":null,"summary":"Reported: GLP-1 FAQs issued in July 2025 stating semaglutide and tirzepatide are no longer compoundable as essentially copies after the shortage ended; a rule limiting advance sterile compounding of weight-loss drugs to 250 doses; summary suspensions of clinics and med spas since early 2025. Reported date is approximate.","source_url":null,"docket":null,"status":"no_information","status_reason":"owner working notes; the board's FAQ, rule, and suspension orders have not been located and linked","verified_on":null,"related_id":null},{"id":2,"action_date":"2025-02-21","actor":"fda","actor_detail":"FDA","jurisdiction":"US","instrument":"order","target":null,"drugs":"semaglutide","statute":"FDCA 503A, 503B","summary":"Declaratory order stating that FDA has determined the shortage of semaglutide injection is resolved. FDA later stated that its enforcement discretion for compounders ended April 22, 2025 (503A) and May 22, 2025 (503B), or on the date of a court decision if later.","source_url":"https://www.fda.gov/media/185526/download","docket":null,"status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null},{"id":14,"action_date":"2025-01-30","actor":"state_board","actor_detail":"Mississippi Board of Nursing","jurisdiction":"MS","instrument":"rule","target":null,"drugs":null,"statute":null,"summary":"Reported: a temporary rule dated January 30, 2025 imposing additional active-ingredient verification on pharmacies supplying compounded weight-loss medications; medical board cease-prescribing directives.","source_url":null,"docket":null,"status":"no_information","status_reason":"owner working notes; the temporary rule and directives have not been located and linked","verified_on":null,"related_id":null},{"id":1,"action_date":"2024-12-19","actor":"fda","actor_detail":"FDA","jurisdiction":"US","instrument":"order","target":null,"drugs":"tirzepatide","statute":"FDCA 503A, 503B","summary":"Declaratory order stating that FDA has determined the shortage of tirzepatide injection is resolved. FDA later stated that its enforcement discretion for compounders ended February 18, 2025 (503A) and March 19, 2025 (503B).","source_url":"https://www.fda.gov/media/184606/download","docket":null,"status":"issued","status_reason":null,"verified_on":"2026-09-22","related_id":null}]